Fig. 3: Geometric mean titers and geometric mean fold rises of SARS-CoV-2 50% neutralizing titers for participants by age group and overall. | Nature Communications

Fig. 3: Geometric mean titers and geometric mean fold rises of SARS-CoV-2 50% neutralizing titers for participants by age group and overall.

From: A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults

Fig. 3

Results are for the evaluable immunogenicity population. Data are presented as geometric mean values with associated 95% CIs shown as error bars. Dots represent individual 50% neutralizing titers; individual dots correspond with discrete visits for each time point and may be superimposed. Numbers within bars are the geometric means. n = Number of participants with valid and determinate assay results. GMTs, GMFRs, and two-sided 95% CIs were calculated by exponentiation of the mean logarithm of the titers or fold rises and the corresponding CIs (based on the Student t distribution). GMFRs are from before dose 1 to 1 month after dose 2. Assay results below the LLOQ (20, dashed line) were set to 0.5 × LLOQ. CI confidence interval, GMFR geometric mean fold rise, GMT geometric mean titer, NT50 50% neutralizing titer, LLOQ lower limit of quantitation, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2. In the placebo group, n = 41 except before dose 2, when n = 40.

Back to article page